Critical Therapeutics announces issuance of US patent for novel anti-inflammatory ...( CAMBRIDGE Mass.--(BUSINESS WIRE)--Sept...)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 2, 2003-- Critical Therapeutics, Inc. (CTI) today announced the issuance of a U.S. patent covering therapies designed to control destructive inflammatory processes by regulating a key reflex pathway between the central nervous system and the major organs.

U.S. Patent No. 6,610,713, entitled "Inhibition of Inflammatory Cytokine Production by Cholinergic Agonists and Vagus Nerve Stimulation," covers methods of treating a broad range of serious inflammatory diseases. The invention described in the patent embodies novel approaches to inhibit the cellular release of pro-inflammatory cytokines through administration of cholinergic receptor agonists or direct stimulation, including electrical stimulation of the vagus nerve. The vagus nerve is a major signaling pathway for the anti-inflammatory signal between the brain and major organs such as the heart, stomach, liver and small intestine.

For decades, researchers thought the vagus nerve was involved chiefly in the process of regulating the function of internal organs. In recent years, however, scientists have discovered that the vagus nerve plays a vital role in regulating the immune system. Specifically, vagus nerve stimulation has been shown to release a substance known as acetylcholine, which in turn inhibits the production by macrophages of pro-inflammatory, potentially lethal proteins called cytokines. It is the immune system's overproduction of these cytokines, including tumor necrosis factor (TNF), that can contribute to illnesses such as rheumatoid arthritis, Crohn's disease, ulcerative colitis and sepsis.

Patent No. 6,610,713 stems from research conducted by the inventor - CTI co-founder Kevin J. Tracey, M.D. - and his colleagues at North Shore-Long Island Jewish Research Institute's Laboratory of Biomedical Research. CTI in-licensed exclusive rights to the patent from the Institute. In an article published in the December 22, 2002 online edition
'"/>

Contact: Scott Solomon
ssolomon@investorrelations.com
617-542-5300
Sharon Merrill Associates, Inc.
2-Sep-2003

Page: 1 2
Related biology news :

1. Critically endangered monkey species plummets more than 50 percent since 1994
2. Save The Tiger Fund announces alliance with the Critical Ecosystem Partnership Fund
3. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
4. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
5. Critical early-defense trigger in plants found
6. Critical therapeutics is awarded U.S. patents for methods to diagnose and treat inflammatory disease
7. Researchers, Regulators, Industry, Consumer Advocates Gather to Discuss Critical Issues Facing the Pharmaceutical Industry
8. Study Furthers Understanding Of Critical Alzheimers Disease Gene
9. Gene Once Thought To Program Ovarian Development Instead Found To Be Critical For Production Of Sperm
10. UF Researchers: Gene Therapy Replaces Critical Protein In Animal Model Of Often-Fatal Lung-Liver Disease
11. Columbia Researchers Synthesize Compound With Possible Link To MacularDegeneration; Work Is Critical To Pinpointing Causes Of Disease, Scientists Say